Stoke Therapeutics Inc (STOK)
NASDAQ:STOK
Total Valuation
Stoke Therapeutics has a market cap or net worth of $1.94B. The enterprise value is $1.85B.
Market Cap$1.94B
Enterprise Value$1.85B
Share Statistics
Stoke Therapeutics has 59,150,790 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding59,150,790
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Stoke Therapeutics’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is -5.71%.
Return on Equity (ROE)-0.02
Return on Assets (ROA)-0.02
Return on Invested Capital (ROIC)-5.71%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee1.44M
Profits Per Employee-53.79K
Employee Count128
Asset Turnover0.44
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Stoke Therapeutics is ―. Stoke Therapeutics’s PEG ratio is 2.94.
PE Ratio―
PS Ratio10.19
PB Ratio5.33
Price to Fair Value5.33
Price to FCF41.85
Price to Operating Cash Flow41.94
PEG Ratio2.94
Income Statement
In the last 12 months, Stoke Therapeutics had revenue of 184.42M and earned -6.88M in profits. Earnings per share was -0.12.
Revenue184.42M
Gross Profit184.42M
Operating Income-20.59M
Pretax Income-6.88M
Net Income-6.88M
EBITDA-18.82M
Earnings Per Share (EPS)-0.12
Cash Flow
In the last 12 months, operating cash flow was 45.59M and capital expenditures -670.00K, giving a free cash flow of 44.91M billion.
Operating Cash Flow45.59M
Free Cash Flow44.91M
Free Cash Flow per Share0.76
Dividends & Yields
Stoke Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.60
52-Week Price Change444.76%
50-Day Moving Average33.15
200-Day Moving Average25.95
Relative Strength Index (RSI)47.40
Average Volume (3m)905.88K
Important Dates
Stoke Therapeutics upcoming earnings date is May 11, 2026, Before Open (Confirmed).
Last Earnings DateMar 11, 2026
Next Earnings DateMay 11, 2026
Ex-Dividend Date―
Financial Position
Stoke Therapeutics as a current ratio of 5.28, with Debt / Equity ratio of 0.00%
Current Ratio5.28
Quick Ratio5.28
Debt to Market Cap0.00
Net Debt to EBITDA4.48
Interest Coverage Ratio-1.50
Taxes
In the past 12 months, Stoke Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Stoke Therapeutics EV to EBITDA ratio is -95.40, with an EV/FCF ratio of 39.97.
EV to Sales9.74
EV to EBITDA-95.40
EV to Free Cash Flow39.97
EV to Operating Cash Flow39.39
Balance Sheet
Stoke Therapeutics has $284.67M in cash and marketable securities with $0.00 in debt, giving a net cash position of $284.67M billion.
Cash & Marketable Securities$284.67M
Total Debt$0.00
Net Cash$284.67M
Net Cash Per Share$4.81
Tangible Book Value Per Share$5.95
Margins
Gross margin is 98.89%, with operating margin of -11.16%, and net profit margin of -3.73%.
Gross Margin98.89%
Operating Margin-11.16%
Pretax Margin-3.73%
Net Profit Margin-3.73%
EBITDA Margin-10.20%
EBIT Margin-11.16%
Analyst Forecast
The average price target for Stoke Therapeutics is $46.71, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$46.71
Price Target Upside42.67% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast1128.17%
EPS Growth Forecast―